You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PI3Kδ inhibitor

Showing 26 - 50 of 9,806
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Solid Tumor Trial

Withdrawn
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • (no location specified)
May 24, 2022

Locally Advanced Breast Cancer, Metastatic Breast Cancer Trial in Batumi, Tbilisi (Tenalisib)

Active, not recruiting
  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Batumi, Georgia
  • +2 more
May 2, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
Jun 27, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

Ovarian Cancer, Breast Cancer, Solid Tumor Trial in Houston, Brisbane (CYH33)

Recruiting
  • Ovarian Cancer
  • +4 more
  • New Haven, Connecticut
  • +6 more
Oct 10, 2022

PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer Trial (RLY-5836, Fulvestrant, Palbociclib)

Not yet recruiting
  • PIK3CA Mutation
  • +7 more
  • (no location specified)
Mar 7, 2023

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022

Breast Cancer, Gynecologic Cancer, HNSCC Trial in Boston (STX-478, Fulvestrant)

Recruiting
  • Breast Cancer
  • +3 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Mar 13, 2023

Colorectal Cancer, Gastric Cancer, HER2-negative Breast Cancer Trial (TOS-358)

Not yet recruiting
  • Colorectal Cancer
  • +8 more
  • (no location specified)
Jan 5, 2023

Brain and CNS Tumors Trial in Memphis (GDC-0084, radiation therapy)

Completed
  • Brain and Central Nervous System Tumors
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 13, 2023

Healthy Trial in Nottingham ([14C]-Paxalisib Capsule)

Active, not recruiting
  • Healthy
  • [14C]-Paxalisib Capsule
  • Nottingham, United Kingdom
    Quotient Sciences
Aug 16, 2022

Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

Recruiting
  • Metastatic Breast Cancer
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

Follicular Lymphoma, Endometrial Cancer Trial in New York (Copanlisib, Ketogenic Diet)

Recruiting
  • Follicular Lymphoma
  • Endometrial Cancer
  • New York, New York
  • +2 more
Nov 24, 2021

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

Recruiting
  • Salivary Gland Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Feb 18, 2022

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
Mar 9, 2022

HNSCC Trial in Houston (Bimiralisib)

Terminated
Has Results
  • HNSCC
  • Houston, Texas
    M.D. Anderson Cancer Center
Dec 22, 2021

Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis Trial in Worldwide (parsaclisib, ruxolitinib,

Recruiting
  • Myelofibrosis
  • +3 more
  • Anchorage, Alaska
  • +172 more
Dec 1, 2022

Unresectable Melanoma Trial in Pittsburgh (Nivolumab, Duvelisib)

Recruiting
  • Unresectable Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Apr 19, 2022

Lymphoma Trial in Worldwide (HMPL-689)

Active, not recruiting
  • Lymphoma
  • Anaheim, California
  • +26 more
Jan 11, 2023

Advanced Gastric Adenocarcinoma Trial in Seoul (GSK2636771, Paclitaxel)

Completed
  • Advanced Gastric Adenocarcinoma
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System, Yonsei Canc
Apr 21, 2021

Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Zandelisib (ME-401))

Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Zandelisib (ME-401)
  • Tucson, Arizona
  • +115 more
Mar 8, 2022

Advanced Hepatocellular Carcinoma Trial in La Jolla (SF1126, Nivolumab)

Terminated
  • Advanced Hepatocellular Carcinoma
  • La Jolla, California
    UC San Diego Moores Cancer Center
May 11, 2022

Esophageal Cancer Trial in Hat yai (BKM120)

Terminated
  • Esophageal Cancer
  • Hat yai, Songkhla, Thailand
    Songklanagarind Hospital, Prince of Songkla University
Oct 3, 2021